Merck & Co., Inc. (MRCK34.SA)
| Previous Close | 84.57 |
| Open | 84.32 |
| Bid | 82.26 x 0 |
| Ask | 84.88 x 0 |
| Day's Range | 84.32 - 84.52 |
| 52 Week Range | 61.00 - 85.35 |
| Volume | |
| Avg. Volume | 8,152 |
| Market Cap | 1.713T |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | 145.72 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.36 (1.61%) |
| Ex-Dividend Date | Mar 14, 2024 |
| 1y Target Est | N/A |
- Business Wire
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
RAHWAY, N.J., May 15, 2024--Merck to Present New Data at 2024 ASCO Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
- Business Wire
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
RAHWAY, N.J., May 13, 2024--Merck Update on KeyVibe-010 Evaluating Coform of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients W/ Resected High-Risk Melanoma
- CNW Group
Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with gemcitabine-based chemotherapy, for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma (BTC). This approval is based on the results from the Phase 3 KEYNOTE-966 trial, which demonstrated a statistically significant and clinically meaningful improvem
